



## Bulletin from the annual general meeting in Klaria Pharma Holding AB (publ)

Today, the annual general meeting of 2023 was held in Klaria Pharma Holding AB (publ). Below follows a summary of the resolutions passed at the annual general meeting (all in accordance with the proposals presented in the notice to attend the meeting kept available at the company's website [www.klaria.com](http://www.klaria.com)).

- It was resolved to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2022.
- It was resolved that the company's available funds shall be carried forward in new account.
- It was unanimously resolved to discharge the board of directors and the CEO from liability for their management of the company's business during the financial year 2022.
- It was resolved to re-elect Fredrik Hübinette, Scott Boyer and Anders Jacobson as board members. Fredrik Hübinette was re-elected as chairman of the board.
- It was resolved to re-elect the accounting firm BDO Mälardalen AB as auditor with authorized auditor Niclas Nordström as auditor-in-charge.
- The fees payable to the members of the board of directors were determined to SEK 200,000 per board member not employed by the company. Scott Boyer and Fredrik Hübinette are employed by the company, entailing that fees will only be paid to Anders Jacobson. It was resolved that the company's auditor shall be paid in accordance with approved invoices.
- It was resolved to change the limits in the articles of association with respect to share capital and number of shares, whereby the company's share capital shall be not less than SEK 1,700,000 and not more than SEK 6,800,000 and the number of shares shall be no less than 100,000,000 and no more than 400,000,000.
- It was resolved to authorise the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures through which the company's share capital may be increased by an amount corresponding to 20 per cent of the share capital and number of shares in the company as of on the date the board of directors make use of the authorisation.

**For more information, visit the Klaria Pharma Holding website [klaria.com](http://klaria.com) or contact:**

Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)

[investor.relations@klaria.com](mailto:investor.relations@klaria.com)

Tel: +46 (0) 8-446 42 99

**This is Klaria Pharma Holding AB**

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor ([info@fnca.se](mailto:info@fnca.se), +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see [www.klaria.com](http://www.klaria.com).